Skip to main content

fluconazole

Generic: FLUCONAZOLE·Brand: DIFLUCAN, DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, DIFLUCAN IN SODIUM CHLORIDE 0.9%, DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, Diflucan, FLUCONAZOLE, FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

fluconazole: 7 clinical trials tracked.

fluconazole evidence translation

What we can confirm

7 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about fluconazole, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 4 study sponsors
Clinical Trials (7)

The Drug-Drug Interaction Study of Clifutinib

NCT07341672·Phase 1
Not yet recruiting

Primary endpoint: Cmax

InterventionalRandomizedopen80 targetStarted 2026-12Completion 2027-051 site · ChinaSunshine Lake Pharma Co., Ltd.

A Phase 1, Open-Label, Fixed-Sequence Study to Investigate the Effect of Fluconazole on the Pharmacokinetics of Olomorasib (LY3537982) in Healthy Participants

NCT07439250·Phase 1·LLY
Completed

Primary endpoint: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Olomorasib

Interventionalopen15 enrolledStarted 2026-03Completion 2026-041 site · United StatesEli Lilly and Company

A Phase 1 Crossover Design Study to Assess the Effect of CYP3A Moderate and Strong Inhibitors (Fluconazole and Itraconazole) and Strong Inducer (Carbamazepine) on the Single-dose Pharmacokinetics of ASP3082 in Healthy Adults

NCT07395024·Phase 1·ENTA
Not yet recruiting

Primary endpoint: Pharmacokinetics (PK) of ASP3082 in plasma: Maximum Concentration (Cmax) in ASP3082

Interventionalopen54 targetStarted 2026-02Completion 2026-07Astellas Pharma Global Development, Inc.

A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD, CROSSOVER STUDY IN HEALTHY PARTICIPANTS TO INVESTIGATE THE EFFECT OF FLUCONAZOLE ON PF-07248144 PHARMACOKINETICS

NCT07636018·Phase 1·PFE
Completed

Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PF-07248144 - Period 1

Interventionalopen12 enrolledStarted 2025-08Completion 2025-111 site · BelgiumPfizer

A Non-Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine, and Fluconazole on the Pharmacokinetics and Safety of EDP-323 in Healthy Participants

NCT06847464·Phase 1·ENTA
Completed

Primary endpoint: Cmax of EDP-323 with and without coadministration with Itraconazole

Interventionalopen48 enrolledStarted 2025-01Completion 2025-061 site · United StatesEnanta Pharmaceuticals, Inc

A Phase 1, Single-Center, Open-Label, 3-Cohort, Fixed-Sequence, Drug-Drug Interaction Study To Assess The Pharmacokinetics Of LY4100511 (DC-853) When Orally Administered Alone, When Coadministered With Itraconazole, Fluconazole, Or Carbamazepine In Healthy Adult Participants

NCT06345794·Phase 1·LLY
Completed

Primary endpoint: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY4100511 (DC-853)

Interventionalopen50 enrolledStarted 2024-04Completion 2024-061 site · United StatesDICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin Followed by Oral Ibrexafungerp Versus Intravenous Echinocandin Followed by Oral Fluconazole (MARIO)

NCT05178862·Phase 3·SCYX
Terminated

Primary endpoint: All-cause Mortality

InterventionalRandomizedquadruple68 enrolledStarted 2022-08Completion 2025-1250 sites · Belgium, Bulgaria, Canada, China…Scynexis, Inc.